head and neck cancer – Page 3

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

By MedXY 10/25/2025

Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting.

Clinical Updates Oncology Specialties

Advancing Immunotherapy in Head and Neck Cancer: A Curcumin-Based Polymer Prodrug Nanoplatform Targeting Cancer Stemness and Tumor Microenvironment

By MedXY 09/29/2025

A novel curcumin-based polymer prodrug nanoplatform enhances immunotherapy in head and neck cancer by targeting tumor cell stemness and reversing immunosuppression via synergistic photothermal, photodynamic, and ferroptosis mechanisms.

Clinical Updates news Oncology Specialties

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

By MedXY 09/08/2025

The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cell carcinoma of the head and neck.

news Oncology Specialties

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Squamous-Cell Carcinoma: A Phase 3 Trial Overview and Clinical Implications

By MedXY 08/19/2025

The phase 3 KEYNOTE-689 trial demonstrates that adding perioperative pembrolizumab to surgery and adjuvant therapy significantly improves event-free survival in locally advanced HNSCC without compromising surgical outcomes or safety.

Clinical Updates news Oncology Radiology Specialties

Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial

By MedXY 08/07/2025

The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurrence risk.

Clinical Updates news Oncology Specialties

Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer

By MedXY 08/07/2025

A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.